TIX100
Type 1 Diabetes, Type 2 Diabetes, MASLD/MASH
Phase 1Active
Key Facts
About TIXiMED
TIXiMED is pioneering a novel therapeutic approach for diabetes and related metabolic disorders by targeting the protein TXNIP, a key regulator of pancreatic beta-cell function and glucagon secretion. Its lead candidate, TIX100, is an oral small molecule that has successfully completed a Phase 1 single ascending dose study and shows promise in addressing significant unmet needs, including a potential oral therapy for Type 1 Diabetes and a treatment for MASLD. The company leverages strong academic origins, exclusive intellectual property, and a seasoned leadership team with deep expertise in diabetes drug development and commercialization.
View full company profile